"As it works to expand its antibody-drug conjugate (ADC) capabilities, Merck has strengthened its links to Starpharma by signing a second partnership that will allow it to assess potential candidates using a dendrimer drug delivery technology", reports World Pharma Today.

"Merck has tightened its ties to Starpharma as it continues to build out its antibody-drug conjugate (ADC) capabilities, signing a second agreement that will enable it to evaluate candidates based on a dendrimer drug delivery platform", as featured in Fierce Pharma. 

"Starpharma (ASX:SPL) has announced a new research agreement with MSD under which the Australian company will design and synthesise a number of DEP dendrimer conjugates and provide them to the US-based company for testing and characterisation," as reported in The National Tribune.

Starpharma today announced it has signed a new DEP^® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new agreement follows an earlier DEP^® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021. Under the new agreement, Starpharma will design and synthesize a number of DEP^® dendrimer conjugates and will provide them to MSD for testing and characterisation.